HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

5- (5- amino- 3- (4- fluorophenyl)pyrazin- 2- yl)- 1- isopropylprydine- 2(1H)- one

structure in first source

Also Known As:

ASP 5854; ASP-5854; ASP5854

Networked: 3 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Aminopyridines: 77
    - 5-(5-amino-3-(4-fluorophenyl)pyrazin-2-yl)-1-isopropylprydine-2(1H)-one: 3
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Aminopyridines: 77
      - 5-(5-amino-3-(4-fluorophenyl)pyrazin-2-yl)-1-isopropylprydine-2(1H)-one: 3
  - Piperazines: 26
    - 5-(5-amino-3-(4-fluorophenyl)pyrazin-2-yl)-1-isopropylprydine-2(1H)-one: 3

Experts

1.	Iwashita, Akinori: 3 articles (12/2008 - 11/2007)
2.	Matsuoka, Nobuya: 3 articles (12/2008 - 11/2007)
3.	Mihara, Takuma: 3 articles (12/2008 - 11/2007)
4.	Mihara, Kayoko: 2 articles (07/2008 - 11/2007)
5.	Arai, Hiroshi: 1 article (07/2008)
6.	Matsuya, Takahiro: 1 article (07/2008)
7.	Miyoshi, Sosuke: 1 article (07/2008)
8.	Murakami, Yoshihiro: 1 article (07/2008)
9.	Nishimura, Shintaro: 1 article (07/2008)
10.	Noda, Akihiro: 1 article (07/2008)

Related Diseases

1.	Catalepsy 07/01/2008 - "In addition, more than 85% A(2A)R occupancy by ASP5854 resulted in an inhibition of haloperidol-induced catalepsy. " 07/01/2008 - "The purpose of the present study was to measure adenosine A(2A) receptor (A(2A)R) occupancy in the brain by a novel adenosine A(1)/A(2A) antagonist, 5-[5-amino-3-(4fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), and to determine the degree of receptor occupancy necessary to inhibit haloperidol-induced catalepsy in rhesus monkeys. " 11/01/2007 - "ASP5854 ameliorated A(2A) agonist 2-[p-(2-carboxyethyl) phenethylamino]-5'-N-ethylcarboxamidoadenosine (CGS21680)- and haloperidol-induced catalepsy in mice, with the minimum effective doses of 0.32 and 0.1 mg/kg, respectively, and it also improved haloperidol-induced catalepsy in rats at doses higher than 0.1 mg/kg. In unilateral 6-hydroxydopamine-lesioned rats, ASP5854 significantly potentiated l-dihydroxyphenylalanine (L-DOPA)-induced rotational behavior at doses higher than 0.032 mg/kg. ASP5854 also significantly restored the striatal dopamine content reduced by 1-metyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment in mice at doses higher than 0.1 mg/kg. Furthermore, in the rat passive avoidance test, ASP5854 significantly reversed the scopolamine-induced memory deficits, whereas the specific adenosine A(2A) antagonist 8-((E)-2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione (KW-6002; istradefylline) did not. "
2.	Parkinson Disease (Parkinson's Disease) 11/01/2007 - "Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition." 12/12/2008 - "A novel adenosine A(1) and A(2A) receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: comparison with existing anti-Parkinson's disease drugs."
3.	Memory Disorders (Memory Loss) 11/01/2007 - "ASP5854 ameliorated A(2A) agonist 2-[p-(2-carboxyethyl) phenethylamino]-5'-N-ethylcarboxamidoadenosine (CGS21680)- and haloperidol-induced catalepsy in mice, with the minimum effective doses of 0.32 and 0.1 mg/kg, respectively, and it also improved haloperidol-induced catalepsy in rats at doses higher than 0.1 mg/kg. In unilateral 6-hydroxydopamine-lesioned rats, ASP5854 significantly potentiated l-dihydroxyphenylalanine (L-DOPA)-induced rotational behavior at doses higher than 0.032 mg/kg. ASP5854 also significantly restored the striatal dopamine content reduced by 1-metyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment in mice at doses higher than 0.1 mg/kg. Furthermore, in the rat passive avoidance test, ASP5854 significantly reversed the scopolamine-induced memory deficits, whereas the specific adenosine A(2A) antagonist 8-((E)-2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione (KW-6002; istradefylline) did not. "

Related Drugs and Biologics

1.	Adenosine (Adenocard)
2.	Haloperidol (Haldol)
3.	Adenosine-5'-(N-ethylcarboxamide) (NECA)
4.	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
5.	Scopolamine (Hyoscine)
6.	Levodopa (L Dopa)
7.	Dopamine (Intropin)
8.	Dihydroxyphenylalanine (Dopa)
9.	istradefylline
10.	P-2 (P 2)